Description
Book SynopsisMyocardial viability has become one of the most important issues in clinical cardiology. In particular, absence or presence of viability may be decisive in patient management, and the decision to perform angioplasty (PTCA) or bypass surgery (CABG) is frequently based on the accurate assessment of viability. Although echocardiography and conventional nuclear medicine techniques may provide valuable information on viability, positron emission tomography (PET) is currently considered to be the gold standard for the assessment of myocardial viability. The simultaneous evaluation of myocardial metabolism and perfusion allows precise delineation and accurate quantification of residual myocardial viability in affected regions. In addition, accurate quantification of myocardial perfusion alone may provide insight into the basic mechanisms of syndrome X and may assist in the appropriate clarification of this clinically complicated, but frequently occurring phenomenon.
Besides that, cardiac PET may deepen our insight into metabolism and perfusion of cardiac muscle disease, particularly in hypertrophic cardiomyopathy. Furthermore, receptor imaging studies with PET will become important as the study of cardiac neurohumoral regulation in heart failure has gained in interest.
Cardiac Positron Emission Tomography: Viability, Perfusion, Receptors and Cardiomyopathy describes the most recent developments in cardiac PET as these are related to myocardial viability and myocardial perfusion studies of syndrome X. The value of PET for receptor imaging and cardiac muscle disease is also discussed.
For cardiologists, nuclear medicine physicians, radiochemists, physiologists, technicians and basic researchers interested in understanding the most recent achievements in cardiovascular PET.
Trade Review`This small, condensed and well-produced book gives a detailed account of the cardiac PET conference ... The book is clearly inteded for committed investigators and clinicians whose main interest is cardiology, but it is highly recommended as an up-to-date well-produced publication that deserves to be read, digested and kept for future specialized reference.
' European Journal of Nuclear Medicine 22:10, 1995Table of ContentsPreface; W. Vaalburg, Kong I. Lie. Foreword; E.E. van der Wall, P.K. Blanksma, M.G. Niemeyer, A.M.J. Paans. State of the art in cardiac positron emission tomography; P.G. Camici. Part One: Myocardial Viability. 1. Myocardial viability: stunning and hibernation; W. Flameng, B. Shivalkar, M. Borgers. 2. Positron emission tomography assessment of myocardial viability; Eng-Shiong Tan. 3. Comparison of thallium scintigraphy and positron emission tomography; M.G. Niemeyer, J.G. Meeder, A.F.M. Kuijper, P.K. Blanksma, E.E. van der Wall. 4. Cardiac metabolism: positron emission tomography versus single photon emission computed tomography; E.E. van der Wall. 5. The role of fluorine-19-deoxyglucose single photon emission computed tomography in predicting reversibility of regional wall motion abnormalities after revascularization; J.J. Bax, J.H. Cornel, F.C. Visser, P.M. Fioretti, A. van Lingen, J.M. Huitink, O. Kamp, G.J.J. Teule, C.A. Visser. 6. Parametric positron emission tomography imaging of myocardial perfusion and metabolism; A.T.M. Willemsen, P.K. Blanksma, A.M.J. Paans. 7. Positron emission tomography compared to single photo emission computed tomography in the evaluation of myocardial viability: a preliminary cost-effectiveness analysis; M.G.M. Hunink. 8. Assessment of myocardial viability by pharmacological stress echocardiography; J.H. Cornel, M.P. Fioretti. 9. Assessment of myocardial viability by magnetic resonance imaging techniques; C.A. Schneider, F. Baer, E. Voth, P. Theissen, U. Sechtem. Part Two: Hypertrophic Cardiomyopathy. 10. Classification of hypertrophic cardiomyopathy with magnetic resonance imaging compared with echocardiography; J.L. Posma, P.K. Blanksma, Kong I. Lie. 11. Positron emission tomography characterization of the myocardium in hypertrophic cardiomyopathy; P.K. Blanksma, J.L. Posma, R.M. de Jong, J. Pruim, A.T.M. Willemsen, R.L. Anthonio, E. van der Wall, W. Vaalburg, Kong I. Lie. 12. Treatment of hypertrophic obstructive cardiomyopathy with pacing; L. Kappenberger, X. Jeanrenaud, N. Aebischer. Part Three: Receptor Imaging Studies. 13. Heart failure and the cardiac beta-adrenoceptor; O.-E. Brodde. 14. Study of cardiac receptor ligands by positron emission tomography; A. van Waarde, P.H. Elsinga, R.L. Anthonio, T.J. Visser, P.K. Blanksma, G.M. Visser, A.M.J. Paans, W. Vaalburg. 15. Assessment of sympathetic cardiac innervation by scintigraphic techniques; G. Münch, Ngoc Nguyen, D. Wieland, M. Schwaiger. 16. Experimental and clinical cardiac beta-receptor studies; R.L. Anthonio, A. van Waarde, A.T.M. Willemsen, J. Pruim, W.H. van Gilst, P.K. Blanksma, W. Vaalburg, Kong I. Lie. Part Four: Myocardial Perfusion. 17. Methodological issues in regional myocardial perfusion imaging with positron emission tomography; A. Bol, W. Wijns, J.A. Melin. 18. Altered autonomic control of the cardiovascular system in syndrome X; J.G. Meeder. 19. Positron emission tomography studies of cardiac neurostimulation; R.W.M. Hautvast. Index.
